KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Invested Capital (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Invested Capital for 18 consecutive years, with $31.4 billion as the latest value for Q1 2026.

  • For Q1 2026, Invested Capital rose 6.93% year-over-year to $31.4 billion; the TTM value through Mar 2026 reached $31.4 billion, up 6.93%, while the annual FY2025 figure was $32.0 billion, 2.04% up from the prior year.
  • Invested Capital hit $31.4 billion in Q1 2026 for Regeneron Pharmaceuticals, down from $32.0 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $32.0 billion in Q4 2025 and bottomed at $20.7 billion in Q1 2022.
  • Average Invested Capital over 5 years is $26.9 billion, with a median of $27.0 billion recorded in 2024.
  • Year-over-year, Invested Capital surged 62.42% in 2022 and then rose 2.04% in 2025.
  • Regeneron Pharmaceuticals' Invested Capital stood at $23.4 billion in 2022, then rose by 14.14% to $26.7 billion in 2023, then increased by 17.31% to $31.3 billion in 2024, then rose by 2.04% to $32.0 billion in 2025, then fell by 1.73% to $31.4 billion in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $31.4 billion, $32.0 billion, and $31.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.